

Title (en)
METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT AND MANAGEMENT OF MACULAR DEGENERATION

Title (de)
VERFAHREN ZUR VERWENDUNG VON UNDZUSAMMENSETZUNGEN MIT SELEKTIVEN ZYTOKIN-HEMMERN ZUR BEHANDLUNG UNDVERSORGUNG VON MAKULADEGENERATION

Title (fr)
METHODES D'UTILISATION ET COMPOSITIONS CONTENANT DES SUBSTANCES MEDICAMENTEUSES D'INHIBITION SELECTIVE DES CYTOKINES POUR TRAITER ET CONTROLER LA DEGENERESCENCE

Publication
EP 1567148 A2 20050831 (EN)

Application
EP 03779423 A 20031031

Priority
• US 0334535 W 20031031
• US 42290002 P 20021031

Abstract (en)
[origin: WO2004041181A2] Methods of treating, preventing and/or managing macular degeneration are disclosed. Specific embodiments encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

IPC 1-7
A61K 31/40; **A61K 31/00**

IPC 8 full level
A61K 31/40 (2006.01); **A61K 31/00** (2006.01); **A61K 31/4035** (2006.01); **A61K 31/454** (2006.01); **A61K 31/522** (2006.01); **A61K 31/545** (2006.01); **A61K 31/557** (2006.01); **A61K 31/56** (2006.01); **A61K 38/18** (2006.01); **A61K 38/21** (2006.01); **A61K 38/27** (2006.01); **A61P 27/02** (2006.01)

CPC (source: EP KR)
A61K 31/40 (2013.01 - KR); **A61K 31/404** (2013.01 - KR); **A61K 31/454** (2013.01 - EP); **A61K 31/522** (2013.01 - EP); **A61K 31/545** (2013.01 - EP); **A61K 31/557** (2013.01 - EP); **A61K 31/56** (2013.01 - EP); **A61K 38/185** (2013.01 - EP); **A61K 38/21** (2013.01 - EP); **A61K 38/27** (2013.01 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 27/02** (2017.12 - EP)

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

DOCDB simple family (publication)
WO 2004041181 A2 20040521; **WO 2004041181 A3 20050217**; AU 2003285107 A1 20040607; AU 2003285107 B2 20080110; BR 0315889 A 20051004; CA 2504263 A1 20040521; CN 1731997 A 20060208; EP 1567148 A2 20050831; EP 1567148 A4 20100915; JP 2006509743 A 20060323; KR 20050062649 A 20050623; MX PA05004486 A 20050726; NZ 540185 A 20080131; TW 200418455 A 20041001; ZA 200503468 B 20061025

DOCDB simple family (application)
US 0334535 W 20031031; AU 2003285107 A 20031031; BR 0315889 A 20031031; CA 2504263 A 20031031; CN 200380108090 A 20031031; EP 03779423 A 20031031; JP 2004550274 A 20031031; KR 20057007608 A 20050429; MX PA05004486 A 20031031; NZ 54018503 A 20031031; TW 92130486 A 20031031; ZA 200503468 A 20031031